Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 3
2009 1
2010 2
2011 2
2012 3
2013 2
2014 1
2015 4
2017 1
2018 1
2019 1
2020 2
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy in Patients Clinically Suspected of FSHD Using Optical Genome Mapping.
Guruju NM, Jump V, Lemmers R, Van Der Maarel S, Liu R, Nallamilli BR, Shenoy S, Chaubey A, Koppikar P, Rose R, Khadilkar S, Hegde M. Guruju NM, et al. Among authors: koppikar p. Neurol Genet. 2023 Nov 22;9(6):e200107. doi: 10.1212/NXG.0000000000200107. eCollection 2023 Dec. Neurol Genet. 2023. PMID: 38021397 Free PMC article.
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.
Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Shank K, et al. Among authors: koppikar p. Haematologica. 2020 Mar;105(3):e91-e94. doi: 10.3324/haematol.2018.203729. Epub 2019 Aug 14. Haematologica. 2020. PMID: 31413098 Free PMC article. No abstract available.
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.
Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Wen QJ, et al. Among authors: koppikar p. Nat Med. 2015 Dec;21(12):1473-80. doi: 10.1038/nm.3995. Epub 2015 Nov 16. Nat Med. 2015. PMID: 26569382 Free PMC article.
AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD. Khan I, et al. Among authors: koppikar p. Leukemia. 2013 Sep;27(9):1882-90. doi: 10.1038/leu.2013.167. Epub 2013 Jun 10. Leukemia. 2013. PMID: 23748344 Free PMC article.
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T. Brauchle B, et al. Among authors: koppikar p. Mol Cancer Ther. 2020 Sep;19(9):1875-1888. doi: 10.1158/1535-7163.MCT-19-1093. Epub 2020 Jun 9. Mol Cancer Ther. 2020. PMID: 32518207
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M. Kucine N, et al. Among authors: koppikar p. Blood. 2015 Nov 26;126(22):2479-83. doi: 10.1182/blood-2015-03-635821. Epub 2015 Oct 6. Blood. 2015. PMID: 26443624 Free PMC article. Clinical Trial.
27 results